OFIX

+ Watchlist + Portfolio

Orthofix Medical Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $9.21
52-Week Range: $8.50 – $16.99
Market Cap: $370.26M
P/E (TTM): —
EPS (TTM): -1.52
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.86
PEG Ratio: 48.83
Return on Equity: -13.91%
Return on Assets: -2.74%
Gross Margin: 71.26%
Operating Margin: -3.26%
Profit Margin: -7.41%
Current Ratio: 2.84
Debt/Equity: 0.61
Total Debt: $261.90M
Free Cash Flow: $4.10M
Revenue Growth: 3.80%
Earnings Growth: —
Enterprise Value: $528.35M

OFIX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$460.71M	$746.64M	$799.49M	$822.31M
Cost of Revenue	$123.54M	$260.37M	$253.61M	$256.30M
Gross Profit	$337.17M	$486.27M	$545.88M	$566.02M
Research & Development	$49.06M	$80.23M	$73.64M	$65.85M
Selling, General & Admin	$308.78M	$530.39M	$532.52M	$554.33M
Operating Expenses	$366.04M	$628.03M	$623.60M	$648.59M
Operating Income	-$28.87M	-$141.76M	-$77.72M	-$82.57M
EBITDA	$15.66M	-$79.49M	-$18.28M	$9.93M
Pretax Income	-$17.71M	-$148.68M	-$123.88M	-$90.81M
Income Tax	$2.04M	$2.72M	$2.12M	$1.38M
Net Income	-$19.75M	-$151.40M	-$126.00M	-$92.19M
Diluted EPS	-0.98	-4.12	-3.30	-2.33
Diluted Shares	20.10M	36.73M	38.10M	39.60M

OFIX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$50.70M	$33.11M	$83.24M	$82.03M
Receivables	$82.86M	$128.10M	$134.71M	$135.75M
Inventory	$100.15M	$222.17M	$189.45M	$172.32M
Current Assets	$255.99M	$420.44M	$433.29M	$416.85M
Total Assets	$458.63M	$925.32M	$893.29M	$850.65M
Current Liabilities	$83.62M	$165.22M	$168.63M	$170.48M
Long-Term Debt	—	$93.11M	$157.01M	$157.39M
Total Debt	$21.53M	$117.07M	$179.63M	$178.44M
Total Liabilities	$121.77M	$326.58M	$390.17M	$400.61M
Retained Earnings	$1.25M	-$150.14M	-$276.14M	-$368.33M
Shareholders' Equity	$336.86M	$598.73M	$503.12M	$450.04M
Working Capital	$172.37M	$255.22M	$264.66M	$246.37M
Net Debt	—	$61.25M	$73.78M	$75.37M

OFIX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$11.54M	-$45.75M	$25.79M	$33.35M
Capital Expenditure	-$23.16M	-$62.05M	-$34.88M	-$34.63M
Free Cash Flow	-$34.70M	-$107.80M	-$9.09M	-$1.28M
Depreciation & Amortisation	$32.08M	$60.56M	$75.96M	$83.25M
Stock-Based Compensation	$18.44M	$35.71M	$32.45M	$28.69M
Investing Cash Flow	-$24.53M	-$33.13M	-$27.58M	-$34.60M
Financing Cash Flow	-$78.00K	$65.32M	$50.71M	-$786.00K
Net Change in Cash	-$36.15M	-$13.56M	$48.92M	-$2.04M

OFIX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$193.65M	$203.12M	$205.63M	$219.91M	$196.71M	$210.93M
Cost of Revenue	$72.03M	$63.59M	$57.11M	$63.57M	$57.16M	$61.23M
Gross Profit	$121.62M	$139.53M	$148.52M	$156.34M	$139.55M	$149.71M
Research & Development	$19.77M	$15.93M	$14.77M	$15.37M	$15.32M	$15.94M
Selling, General & Admin	$132.98M	$136.49M	$148.10M	$136.75M	$134.91M	$138.03M
Operating Expenses	$171.10M	$156.30M	$166.00M	$155.19M	$153.23M	$156.97M
Operating Income	-$49.48M	-$16.77M	-$17.47M	$1.15M	-$13.69M	-$7.27M
EBITDA	-$11.95M	$7.72M	-$3.06M	$17.21M	-$619.00K	$5.45M
Pretax Income	-$52.13M	-$14.22M	-$22.26M	-$2.19M	-$20.83M	-$15.00M
Income Tax	$961.00K	-$142.00K	$533.00K	$30.00K	$74.00K	$801.00K
Net Income	-$53.09M	-$14.08M	-$22.80M	-$2.22M	-$20.91M	-$15.80M
Diluted EPS	-1.35	-0.36	-0.57	-0.06	-0.52	-0.39
Diluted Shares	39.20M	39.50M	39.80M	40.00M	40.40M	40.91M

OFIX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$57.95M	$65.61M	$62.86M	$82.03M	$120.28M	$103.81M
Receivables	$131.87M	$129.56M	$130.81M	$135.75M	$137.78M	$135.82M
Inventory	$174.48M	$172.99M	$174.04M	$172.32M	$177.82M	$184.47M
Current Assets	$390.31M	$395.83M	$394.17M	$416.85M	$461.52M	$446.13M
Total Assets	$823.14M	$837.16M	$832.61M	$850.65M	$886.60M	$873.02M
Current Liabilities	$144.12M	$148.38M	$159.85M	$170.48M	$161.03M	$157.01M
Long-Term Debt	$156.88M	$157.05M	$157.22M	$157.39M	$221.34M	$221.59M
Total Debt	$192.76M	$204.74M	$204.48M	$178.44M	$262.25M	$234.62M
Total Liabilities	$364.85M	$378.81M	$390.12M	$400.61M	$451.42M	$443.84M
Retained Earnings	-$329.24M	-$343.32M	-$366.11M	-$368.33M	-$389.24M	-$405.04M
Shareholders' Equity	$458.29M	$458.35M	$442.49M	$450.04M	$435.19M	$429.18M
Working Capital	$246.19M	$247.45M	$234.32M	$246.37M	$300.49M	$289.12M
Net Debt	$98.93M	$91.44M	$94.36M	$75.37M	$101.06M	$117.78M

OFIX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$18.39M	$11.64M	$12.40M	$27.70M	-$17.61M	-$6.22M
Capital Expenditure	-$6.74M	-$7.11M	-$9.90M	-$10.88M	-$10.66M	-$12.65M
Free Cash Flow	-$25.13M	$4.53M	$2.50M	$16.82M	-$28.27M	-$18.87M
Depreciation & Amortisation	$35.68M	$18.00M	$14.52M	$15.05M	$14.55M	$14.36M
Stock-Based Compensation	$6.47M	$7.82M	$7.18M	$7.21M	$6.53M	$7.74M
Investing Cash Flow	-$6.74M	-$7.10M	-$9.89M	-$10.87M	-$10.52M	-$12.65M
Financing Cash Flow	-$651.00K	$2.64M	-$5.15M	$2.38M	$63.97M	$2.45M
Net Change in Cash	-$25.78M	$7.18M	-$2.64M	$19.20M	$35.84M	-$16.42M

Market Snapshot

About

Global medical device company focused on spine and orthopedic solutions. The company develops and markets surgical implants, biologics, and enabling technologies for spinal disorders and musculoskeletal conditions. Its product portfolio includes bone growth stimulators and regenerative medicine solutions.